New registry aims to uncover heart risks in inflammatory disease patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent 2. Diagnosis of an IMID by a rheumatologist with categorisation into one of the following: i. IMID-'higher risk' CVD: individuals who have a risk of developing CVD (based on traditional risk factors and/or IMID-specific factors) but no history of CVD 1. Coronary artery disease (CAD): specifically, a high pre-test probability of CAD based on clinical risk factors (e.g. QRISK3 score ≥10%) and/or elevated biochemical markers (high-sensitivity C-reactive protein ≥2mg/L and/or Lipoprotein(a) ≥70mg/dL) 2. Myopericardial involvement: Specific IMID and/or cardiovascular indicators that place at increased risk e.g. autoantibody associations, presence of peripheral myositis or other major organ involvement; incidental raised serum cardiac biomarkers (troponin and/or NT-pro BNP), on routine testing ii. Incident (new) IMID-CVD: Patients with IMID that present with a new history of CVD <!-- --> 1. ASCVD i. Major adverse cardiovascular events (MACE): \- Non-fatal myocardial infarction. \- Non-fatal stroke of any classification, including reversible focal neurologic \- Defects with imaging evidence of a new cerebral lesion consistent with ischemia or haemorrhage. ii. Other cardiovascular events not accounted for in the MACE-3 composite 2)a)i: \- Hospitalization for unstable angina \- Coronary revascularization \- Hospitalization for heart failure \- Transient Ischemic Attack (TIA) \- Peripheral Vascular Disease (PVD) * Deep vein thrombosis (VTE) and/or pulmonary embolism \[PE\]. 2. Myopericardial involvement: as diagnosed by a cardiology specialist with 'tier 2' cardiovascular imaging and/or other clinical and biochemical criteria in line with usual care iii. Established IMID-CVD a) Patients with IMID and a history of past cardiovascular event as detailed in 2) a) above. b) Patients with a known history of myopericardial involvement as defined above in 2) b) Biological sub-study inclusion criteria * There are no additional inclusion criteria for this sub-study Extended protocol standard CMR sub-study inclusion criteria. * Participants that receive a CMR scan as standard of care Exclusion Criteria: 1. Age less than 18 years 2. Unable to give informed consent Biological sub-study exclusion criteria: \- There are no additional exclusion criteria for this sub-study CMR sub-study exclusion criteria: Standard of care contraindications to: 1. CMR: metal implant eg metal fragments in the eye, pacemaker; claustrophobia; inability to lie flat 2. Magnetic Resonance Imaging (MRI) contrast: renal failure with estimated glomerular filtration rate (eGFR) \<30,